IMCR logo

Immunocore Holdings (IMCR) Company Overview

Profile

Full Name:

Immunocore Holdings plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

February 5, 2021

Indexes:

Not included

Description:

Immunocore Holdings (IMCR) is a biotechnology company focused on developing innovative T-cell receptor therapies for cancer and other diseases. Their unique technology harnesses the immune system to target and destroy cancer cells, aiming to improve treatment outcomes for patients with various types of tumors.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 27, 25 HC Wainwright & Co.
Buy
Jan 10, 25 Needham
Buy
Dec 13, 24 Morgan Stanley
Equal-Weight
Nov 11, 24 Mizuho
Neutral
Nov 7, 24 Needham
Buy
Oct 24, 24 UBS
Sell
Oct 24, 24 HC Wainwright & Co.
Buy
Oct 11, 24 Morgan Stanley
Overweight
Oct 7, 24 Guggenheim
Neutral
Sep 17, 24 Needham
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade
IMCR
zacks.comJanuary 13, 2025

The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
IMCR
globenewswire.comJanuary 10, 2025

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
IMCR
globenewswire.comDecember 23, 2024

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
IMCR
benzinga.comDecember 13, 2024

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
IMCR
zacks.comDecember 12, 2024

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for December 12th
New Strong Buy Stocks for December 12th
New Strong Buy Stocks for December 12th
IMCR
zacks.comDecember 12, 2024

NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024.

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
IMCR
globenewswire.comDecember 3, 2024

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
IMCR
zacks.comNovember 28, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update
IMCR
globenewswire.comNovember 6, 2024

Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

Immunocore (IMCR) Upgraded to Buy: Here's Why
Immunocore (IMCR) Upgraded to Buy: Here's Why
Immunocore (IMCR) Upgraded to Buy: Here's Why
IMCR
zacks.comNovember 5, 2024

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Immunocore Holdings?
  • Does Immunocore Holdings pay dividends?
  • What sector is Immunocore Holdings in?
  • What industry is Immunocore Holdings in?
  • What country is Immunocore Holdings based in?
  • When did Immunocore Holdings go public?
  • Is Immunocore Holdings in the S&P 500?
  • Is Immunocore Holdings in the NASDAQ 100?
  • Is Immunocore Holdings in the Dow Jones?
  • When was Immunocore Holdings's last earnings report?
  • When does Immunocore Holdings report earnings?
  • Should I buy Immunocore Holdings stock now?

What is the ticker symbol for Immunocore Holdings?

The ticker symbol for Immunocore Holdings is NASDAQ:IMCR

Does Immunocore Holdings pay dividends?

No, Immunocore Holdings does not pay dividends

What sector is Immunocore Holdings in?

Immunocore Holdings is in the Healthcare sector

What industry is Immunocore Holdings in?

Immunocore Holdings is in the Biotechnology industry

What country is Immunocore Holdings based in?

Immunocore Holdings is headquartered in United Kingdom

When did Immunocore Holdings go public?

Immunocore Holdings's initial public offering (IPO) was on February 5, 2021

Is Immunocore Holdings in the S&P 500?

No, Immunocore Holdings is not included in the S&P 500 index

Is Immunocore Holdings in the NASDAQ 100?

No, Immunocore Holdings is not included in the NASDAQ 100 index

Is Immunocore Holdings in the Dow Jones?

No, Immunocore Holdings is not included in the Dow Jones index

When was Immunocore Holdings's last earnings report?

Immunocore Holdings's most recent earnings report was on Nov 6, 2024

When does Immunocore Holdings report earnings?

The next expected earnings date for Immunocore Holdings is Feb 28, 2025

Should I buy Immunocore Holdings stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions